Progenics Pharmaceuticals Shares Outstanding 2006-2018 | PGNX

Current and historical number of shares outstanding for Progenics Pharmaceuticals (PGNX) from 2006 to 2018. Diluted shares outstanding can be defined as the number of shares held by shareholders including insiders but not including a company's treasury shares assuming conversion of all convertible debt, securities, warrants and options.
Progenics Pharmaceuticals Annual Shares Outstanding
(Millions of US $)
2017 $70
2016 $70
2015 $70
2014 $68
2013 $56
2012 $35
2011 $33
2010 $33
2009 $31
2008 $30
2007 $27
2006 $26
2005 $21
Progenics Pharmaceuticals Quarterly Shares Outstanding
(Millions of US $)
Q2 2018 $74
Q1 2018 $73
Q4 2017 $70
Q3 2017 $70
Q2 2017 $70
Q1 2017 $70
Q4 2016 $70
Q3 2016 $70
Q2 2016 $70
Q1 2016 $70
Q4 2015 $70
Q3 2015 $70
Q2 2015 $70
Q1 2015 $70
Q4 2014 $68
Q3 2014 $73
Q2 2014 $70
Q1 2014 $64
Q4 2013 $56
Q3 2013 $61
Q2 2013 $51
Q1 2013 $50
Q4 2012 $35
Q3 2012 $34
Q2 2012 $34
Q1 2012 $34
Q4 2011 $33
Q3 2011 $34
Q2 2011 $34
Q1 2011 $33
Q4 2010 $33
Q3 2010 $33
Q2 2010 $32
Q1 2010 $32
Q4 2009 $31
Q3 2009 $31
Q2 2009 $31
Q1 2009 $31
Q4 2008 $30
Q3 2008 $30
Q2 2008 $30
Q1 2008 $30
Q4 2007 $27
Q3 2007 $27
Q2 2007 $27
Q1 2007 $26
Q4 2006 $26
Q3 2006 $26
Q2 2006 $26
Q1 2006 $25
Q4 2005 $21
Q3 2005 $22
Q2 2005 $20
Q1 2005 $17
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.589B $0.012B
Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics' first-in-class PSMA-targeted technology platform for prostate cancer includes an antibody drug conjugate therapeutic in a two-cohort phase 2 clinical trial and a small molecule imaging agent that has completed patient dosing in a phase 2 trial. Among other assets in its pipeline of targeted radiotherapy and molecular imaging compounds is Azedra(TM), an ultra-orphan radiotherapy candidate also in a phase 2 study under an SPA. Progenics' first commercial product, Relistor(R) (methylnaltrexone bromide) for opioid-induced constipation, is partnered with and marketed by Salix Pharmaceuticals, Inc.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $63.001B 10.81
Teva Pharmaceutical Industries (TEVA) Israel $24.629B 6.88
Mylan (MYL) United Kingdom $19.669B 8.37
Bausch Health Cos (BHC) Canada $7.633B 5.70
Dr Reddy's Laboratories (RDY) India $5.610B 25.06
Mallinckrodt Public Limited Company (MNK) United Kingdom $2.887B 4.91
Akorn (AKRX) United States $2.382B 11.80
Supernus Pharmaceuticals (SUPN) United States $2.339B 25.03
Assembly Biosciences (ASMB) United States $0.930B 0.00
Amphastar Pharmaceuticals (AMPH) United States $0.824B 118.80
CymaBay Therapeutics (CBAY) United States $0.723B 0.00
Voyager Therapeutics (VYGR) United States $0.626B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.610B 0.00
Homology Medicines (FIXX) United States $0.607B 0.00
Corium (CORI) United States $0.324B 0.00
Teligent (TLGT) United States $0.228B 0.00
Sol-Gel Technologies (SLGL) Israel $0.119B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.111B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.071B 0.00
Aevi Genomic Medicine (GNMX) United States $0.069B 0.00
Versartis (VSAR) United States $0.065B 0.00
Evoke Pharma (EVOK) United States $0.041B 0.00
Pernix Therapeutics Holdings (PTX) United States $0.020B 0.00
Acasti Pharma (ACST) Canada $0.017B 0.00
China Pharma Holdings (CPHI) China $0.010B 0.00
Agile Therapeutics (AGRX) United States $0.009B 0.00